Bayer has finalized the sale of its Diabetes Care business to Panasonic Healthcare Holdings. The deal, which was previously announced in June last year, was closed on Jan. 5.
The new stand-alone business has been renamed Ascensia Diabetes Care Holdings with its headquarters in Basel, Switzerland.
The sale included the Contour range of blood glucose monitoring systems as well as other products such as Breeze 2, Elite and Microlet lancing devices.
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
Ineos has completed a major £30 million investment at its Hull manufacturing site, converting the facility to run on clean-burning hydrogen instead of natural gas. This results in a 75% cut in carbon emissions.
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
